An observational study in COVID-19 Infection and Melanoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in COVID-19 by M.D. Anderson Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. COVID-19 · M.D. Anderson Cancer Center.
Among the 14 studies in COVID-19 by M.D. Anderson Cancer Center, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2020, is one of 10 observational ones, and was the 4th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →5 of the 14 studies in COVID-19 by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 11 started in 2020.
This study's planned enrollment of 1,152 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 104 across the 4 interventional studies, 600 across the 10 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
5 of the studies in COVID-19 by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04474301M.D. Anderson Cancer CenterWell-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic | 2026-12-30 |
| NCT05022446M.D. Anderson Cancer CenterThe Impact of COVID-19 on Pulmonary Procedures | 2027-02-02 |
| NCT04650178M.D. Anderson Cancer CenterWell-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials | 2027-04-30 |
| NCT04500600M.D. Anderson Cancer CenterWell-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic | 2027-04-30 |
| NCT04565665M.D. Anderson Cancer CenterStudy of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 14 studies in COVID-19 by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.
PRIMARY OBJECTIVES:
I. Assess experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing, isolation, seropositivity, hospitalization, loss of family or friends); COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms); health, financial and social disruptions; perceived benefits and social support; and health-related quality of life (HRQoL) in melanoma patients who participated in protocol PA15-0336.
II. Evaluate the extent to which COVID-19 experiences are associated with COVID-19-specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and HRQoL.
III. Evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.
IV. Explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.
OUTLINE:
Patients complete a survey over 10 minutes.
Patients who have signed consent for PA15-0336.
Inclusion Criteria:
Patients complete a survey over 10 minutes.
Other: Survey Administration
Complete survey
Experiences during the COVID-19 pandemic
Including exposure, risk factors, testing, isolation, seropositivity, hospitalization, or loss of family or friends.
Time frame: Survey completion Up to 2 months
COVID-19-specific psychological distress
Time frame: Survey completion Up to 2 months
COVID-19-specific health
Time frame: Survey completion Up to 2 months
COVID-19-specific financial and social disruptions
Time frame: Survey completion Up to 2 months
COVID-19-specific perceived benefits and social support
Time frame: Survey completion Up to 2 months
COVID-19-specific health related quality of life (HRQoL)
Time frame: Survey completion Up to 2 months
Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL
Will evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.
Time frame: Survey completion Up to 2 months
Prior lifestyle data
Will explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.
Time frame: Survey completion Up to 2 months
Started Jun 2020 (actual). Primary completion is estimated for Dec 2026, 78 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.